Cargando…
Antitumor necrosis factor-α antibodies as a noveltherapy for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for many cases of cancer-associated mortality. Tumor necrosis factor (TNF)-α is a key mediator of tumor-promoting inflammation. It has been demonstrated that anti-TNF-α treatments have preclinical benefits for multiple types of cancer, however their potential...
Autores principales: | Li, Wei, Jian, Yong-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090380/ https://www.ncbi.nlm.nih.gov/pubmed/30116311 http://dx.doi.org/10.3892/etm.2018.6235 |
Ejemplares similares
-
Lysosome Labilizers Potentiate the Antitumor Effects of Tumor Necrosis Factor‐α
por: Masegi, Tsukio, et al.
Publicado: (1993) -
Expression of caspase-3 and hypoxia inducible factor 1α in hepatocellular carcinoma complicated by hemorrhage and necrosis
por: Liang, Hui, et al.
Publicado: (2021) -
Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis
por: Tavakolpour, Soheil, et al.
Publicado: (2016) -
CRISPR/Cas9-mediated hypoxia inducible factor-1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma
por: Liu, Quan, et al.
Publicado: (2018) -
The Eltrombopag antitumor effect on hepatocellular carcinoma
por: KUROKAWA, TOMOHIRO, et al.
Publicado: (2015)